Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Valby, Denmark, reported phase III findings on the efficacy safety and tolerability of brexpiprazole as adjunctive treatment to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) in a poster presentation at the annual meeting of the American College of Neuropsychopharmacology in Phoenix.